{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:53:07Z","timestamp":1791363187240,"version":"4.3.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Tagraxofusp (TAG), a CD123-directed protein-drug conjugate, is approved in front-line and relapsed\/refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN). Multicenter real-world outcomes and the contribution of up-front consolidation post-TAG remain less defined. We retrospectively analyzed 32 patients with BPDCN treated with frontline TAG (2019\u20132024) across 13 tertiary centers, contextualized against a historical cohort treated before TAG availability (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200940). Patients were elderly (median age 71.5\u2009years) with advanced disease, including skin (93.8%), bone marrow (84.4%), and peripheral blood involvement (53.1%). The overall response rate to TAG was 82.1%, with complete responses in 60.7%. Capillary leak syndrome occurred in 53.1% (grade\u2009\u2265\u20093 in 47.1%), with no unexpected safety signals. With a median follow-up of 18.4\u2009months, 2-year overall survival (OS) and progression-free survival were 40.5% and 30.4%. Nearly half of patients proceeded to allogeneic stem cell transplantation post-TAG, associated with improved survival consistent with the primary analysis and landmark-adjusted analyses (HR 0.25 [0.06\u20131.14];\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.073). Propensity score\u2013matched comparison with the Non-TAG cohort showed comparable 2-year OS (59.4% vs 60.8%;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.9). Frontline TAG was not associated with OS in pooled multivariable regression (HR 0.89 [0.37\u20132.15];\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.803), while peripheral blood involvement remained associated with reduced OS (HR 2.63, 95% CI 1.1\u20136.27;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.03). In this large multicenter real-world cohort, frontline TAG achieved high response rates with manageable toxicity. While unmeasured selection may contribute to the higher transplantation rate after TAG, durable remissions were achieved in patients undergoing post-TAG consolidation, supporting TAG as an induction and bridging strategy to allogeneic stem cell transplantation.\n                  <\/jats:p>","DOI":"10.1186\/s13045-026-01848-w","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:33:41Z","timestamp":1791362021000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of front-line tagraxofusp in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) in a real-world scenario"],"prefix":"10.1186","volume":"19","author":[{"given":"Jan C.","family":"Schroeder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Faustmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snjezana","family":"Janjetovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Ossami","family":"Saidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna K.","family":"Zieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliano Filippini","family":"Velazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Melchardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Baden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hristo","family":"Boyadzhiev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schliemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Henrik","family":"Mikesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Gebauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"von Kroge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Br\u00f6ckelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Hildebrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veit","family":"B\u00fccklein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Wurm-Kuczera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Pabst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maher","family":"Hanoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Lengerke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgenii","family":"Shumilov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Bacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Berning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"issue":"5","key":"1848_CR1","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1182\/blood.V99.5.1556","volume":"99","author":"J Feuillard","year":"2002","unstructured":"Feuillard J, Jacob MC, Valensi F, Maynadie M, Gressin R, Chaperot L, et al. Clinical and biologic features of CD4+CD56+ malignancies. Blood. 2002;99(5):1556\u201363. https:\/\/doi.org\/10.1182\/blood.V99.5.1556.","journal-title":"Blood"},{"issue":"2","key":"1848_CR2","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3324\/haematol.2012.072645","volume":"98","author":"L Pagano","year":"2013","unstructured":"Pagano L, Valentini CG, Pulsoni A, Fisogni S, Carluccio P, Mannelli F, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013;98(2):239\u201346. https:\/\/doi.org\/10.3324\/haematol.2012.072645.","journal-title":"Haematologica"},{"issue":"8","key":"1848_CR3","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1182\/blood.2019001144","volume":"134","author":"J Taylor","year":"2019","unstructured":"Taylor J, Haddadin M, Upadhyay VA, Grussie E, Mehta-Shah N, Brunner AM, et al. Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark. Blood. 2019;134(8):678\u201387. https:\/\/doi.org\/10.1182\/blood.2019001144.","journal-title":"Blood"},{"issue":"17","key":"1848_CR4","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","volume":"380","author":"N Pemmaraju","year":"2019","unstructured":"Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019;380(17):1628\u201337. https:\/\/doi.org\/10.1056\/NEJMoa1815105.","journal-title":"N Engl J Med"},{"issue":"26","key":"1848_CR5","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1200\/JCO.22.00034","volume":"40","author":"N Pemmaraju","year":"2022","unstructured":"Pemmaraju N, Sweet KL, Stein AS, Wang ES, Rizzieri DA, Vasu S, et al. Long-term benefits of tagraxofusp for patients with blastic plasmacytoid dendritic cell neoplasm. J Clin Oncol. 2022;40(26):3032\u201336.","journal-title":"J Clin Oncol"},{"issue":"19","key":"1848_CR6","doi-asserted-by":"publisher","first-page":"4838","DOI":"10.1182\/bloodadvances.2020002474","volume":"4","author":"K Laribi","year":"2020","unstructured":"Laribi K, Baugier de Materre A, Sobh M, Cerroni L, Valentini CG, Aoki T, et al. Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients. Blood Adv. 2020;4(19):4838\u201348.","journal-title":"Blood Adv"},{"issue":"3","key":"1848_CR7","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1182\/blood-2012-08-448613","volume":"121","author":"D Roos-Weil","year":"2013","unstructured":"Roos-Weil D, Dietrich S, Boumendil A, Polge E, Bron D, Carreras E, et al. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European group for blood and marrow transplantation. Blood. 2013;121(3):440\u201346. https:\/\/doi.org\/10.1182\/blood-2012-08-448613.","journal-title":"Blood"},{"issue":"5","key":"1848_CR8","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1007\/s00277-023-05587-7","volume":"103","author":"E Shumilov","year":"2024","unstructured":"Shumilov E, Mazzeo P, Ghandili S, Kunstner A, Weidemann S, Banz Y, et al. Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations. Ann Hematol. 2024;103(5):1587\u201399. https:\/\/doi.org\/10.1007\/s00277-023-05587-7.","journal-title":"Ann Hematol"},{"key":"1848_CR9","doi-asserted-by":"publisher","first-page":"1384172","DOI":"10.3389\/fonc.2024.1384172","volume":"14","author":"P Faustmann","year":"2024","unstructured":"Faustmann P, Schroeder JC, Mix L, Harland L, Riedel A, Vogel W, et al. Real-world evidence on tagraxofusp for blastic plasmacytoid dendritic cell neoplasm - collected cases from a single center and case reports. Front Oncol. 2024;14:1384172.","journal-title":"Front Oncol"},{"issue":"8","key":"1848_CR10","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.1007\/s00277-025-06493-w","volume":"104","author":"M Herling","year":"2025","unstructured":"Herling M, Angelucci E, Benoit TM, Rivoli G, Curti A, Gotze KS, et al. Durable outcomes with manageable safety leading to prolonged survival with tagraxofusp for treatment-naive patients with blastic plasmacytoid dendritic cell neoplasm: real world results from a European named patient program. Ann Hematol. 2025;104(8):4121\u201331.","journal-title":"Ann Hematol"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01848-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01848-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01848-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:33:42Z","timestamp":1791362022000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-026-01848-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1848"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01848-w","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"assertion":[{"value":"27 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. The study protocol was approved by the Ethics Committee (\u00c4rztekammer Westfalen-Lippe 2023-071-f-S). All participating centers obtained local institutional review board\/ethics committee approval","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"C.S.: Honoraria\/Advisory Boards: AbbVie, Astellas, AstraZeneca, BMS, Daiichi Sankyo, Laboratories Delbert, Jazz Pharmaceuticals, Novartis, Otsuka, Pfizer, Roche. Research support (institutional): Jazz Pharmaceuticals. Congress\/travel grants: AbbVie, BMS, Daiichi Sankyo, Jazz Pharmaceuticals, Pfizer. G.L.: received honoraria not related to this manuscript from AbbVie, ADC, AstraZeneca, BeOne, Bristol Myers Squibb, Eli Lilly, Exscientia, Flindr, Genmab, Gilead, GSK, Hexal\/Sandoz, Incyte Corporation, Miltenyi, MSD, Novartis, PentixaPharm, Pierre Fabre, Roche, and Sobi; received consultancy fees and\/or participated in advisory boards not related to this manuscript from AbbVie, ADC, AstraZeneca, BeOne, Bristol Myers Squibb, Eli Lilly, Exscientia, Flindr, Genmab, Gilead, GSK, Hexal\/Sandoz, Incyte Corporation, Miltenyi, MSD, Novartis, PentixaPharm, Pierre Fabre, Roche, and Sobi; received research support not related to this manuscript from AbbVie, AstraZeneca, Gilead, Novartis, and Sobi. P.J.B. is an advisor or consultant for Hexal, Merck Sharp & Dohme (MSD), Need Inc., Stemline, Takeda and Therakos; holds stock options in Need AI, has received honoraria from AstraZeneca, BeOne, Bristol-Myers Squibb\/Celgene (BMS), Lilly, MSD, Need AI, Roche, Stemline and Takeda and reports research funding from BeOne (institution), BMS (institution), MSD (institution) and Takeda (institution). H.K.Z.: Travel grants: GILEAD Kite, Eli Lilly. Honoraria: GILEAD Kite, VITIS GmbH.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"80"}}